title: Differences in the EEG profiles of early and late responders to antipsychotic treatment in first-episode, drug-naive psychotic patients.
abstract: The aim of this study was to search for differences in the EEG of first-episode, drug-naive patients having a schizophrenic syndrome which presented different time courses in response to antipsychotic treatment. Thirteen patients who fulfilled DSM-IV diagnosis for schizophrenia or schizophreniform disorder participated in this study. Before beginning antipsychotic treatment, the EEG was recorded. On the same day psychopathological ratings were assessed using the ADMDP system, and again after 7 and 28 days of treatment. The resting EEG (19 leads) was subject to spectral analysis involving power values for six frequency bands. The score for the schizophrenic syndrome was used to divide the patients into two groups: those who displayed a clinically meaningful improvement of this syndrome (reduction of more than 30%) after 7 days of treatment (early responders, ER) and those who showed this improvement after 28 days (late responders. LR). Analysis of variance for repeated measures between ER, LR and their matched controls with the 19 EEG leads yielded highly significant differences for the factor group in the alpha2 and beta2 frequency band. No difference was found between the slow-wave frequency bands. Compared to controls the LR group showed significantly higher alpha2 and beta2 power and, in comparison to the ER group, significantly higher alpha2 power. There were no significant differences between the ER and the control group. These findings point to differences in brain physiology between ER and LR. The implications for diagnosis and treatment are discussed.
authors.affiliation: University Psychiatric Services, Berne, Switzerland. merlo@puk.unibe.ch
authors.forename: M C
authors.initials: MC
authors.lastname: Merlo
authors.forename: H
authors.initials: H
authors.lastname: Kleinlogel
authors.forename: M
authors.initials: M
authors.lastname: Koukkou
mesh_terms: D000328:Adult; D000513:Alpha Rhythm; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001611:Beta Rhythm; D001931:Brain Mapping; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D019965:Neurocognitive Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents